Amedeo Smart

Free Medical Literature Service

 

Amedeo

COVID-19
  Free Subscription

Articles published in
Lancet Infect Dis
    April 2025
  1. BEJON P, Agweyu A, Ochola-Oyier LI, Hamaluba M, et al
    Rethinking the evidence on COVID-19 in Africa.
    Lancet Infect Dis. 2025 Apr 4:S1473-3099(25)00071.
    >> Share

  2. SAWANO M, Bhattacharjee B, Caraballo C, Khera R, et al
    Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.
    Lancet Infect Dis. 2025 Apr 3:S1473-3099(25)00073.
    >> Share

  3. CAI M, Xu E, Xie Y, Al-Aly Z, et al
    Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(24)00831.
    >> Share

  4. CHODICK G
    Long-term infectious sequelae after SARS-CoV-2 infection should be considered in mild cases too.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(25)00074.
    >> Share

    March 2025
  5. RAMOS B, Vadlamudi NK, Han C, Sadarangani M, et al
    Future immunisation strategies to prevent Streptococcus pneumoniae infections in children and adults.
    Lancet Infect Dis. 2025 Mar 17:S1473-3099(24)00740.
    >> Share

  6. HASLAM E
    Lessons from the COVID-19 pandemic.
    Lancet Infect Dis. 2025 Mar 13:S1473-3099(25)00177.
    >> Share

    February 2025
  7. ZHANG L, Kempf A, Nehlmeier I, Chen N, et al
    Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1.
    Lancet Infect Dis. 2025 Feb 26:S1473-3099(25)00113.
    >> Share

  8. FOCOSI D, Casadevall A
    Sipavibart: when a success changes into a failure.
    Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00812.
    >> Share

  9. HAIDAR G, Thomas S, Loubet P, Baker RI, et al
    Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
    Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00804.
    >> Share

  10. KRAMMER F, Barclay WS, Beer M, Brown IH, et al
    Europe needs a sustainably funded influenza research and response network.
    Lancet Infect Dis. 2025 Feb 17:S1473-3099(25)00068.
    >> Share

  11. CHEN L, Kaku Y, Okumura K, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 LP.8.1 variant.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(25)00079.
    >> Share

  12. PROAL AD, Aleman S, Bomsel M, Brodin P, et al
    Targeting the SARS-CoV-2 reservoir in long COVID.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(24)00769.
    >> Share

  13. WANG Q, Mellis IA, Wu M, Bowen A, et al
    KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2.
    Lancet Infect Dis. 2025 Feb 4:S1473-3099(25)00058.
    >> Share

    January 2025
  14. SUTHAR MS, Manning KE, Ellis ML, Jain S, et al
    The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
    Lancet Infect Dis. 2025 Jan 31:S1473-3099(25)00007.
    >> Share

  15. XIE Y
    COVID-19 versus influenza: the need to align policies with COVID-19 realities.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(25)00001.
    >> Share

  16. BAGER P, Svalgaard IB, Lomholt FK, Emborg HD, et al
    The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022-24.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(24)00806.
    >> Share

  17. LIU J, Yu Y, Yang S, Jian F, et al
    Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.
    Lancet Infect Dis. 2025 Jan 28:S1473-3099(25)00015.
    >> Share

  18. ALVES K, Kotloff K, McClelland RS, Kouassi A, et al
    Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
    Lancet Infect Dis. 2025 Jan 14:S1473-3099(24)00670.
    >> Share

  19. YADAV PD, Patil DY
    Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose.
    Lancet Infect Dis. 2025 Jan 14:S1473-3099(25)00005.
    >> Share

    December 2024
  20. ROJEK A, Fieggen J, Apiyo P, Caluwaerts S, et al
    Ebola disease: bridging scientific discoveries and clinical application.
    Lancet Infect Dis. 2024 Dec 12:S1473-3099(24)00673.
    >> Share

  21. URIU K, Kaku Y, Uwamino Y, Fujiwara H, et al
    Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC.
    Lancet Infect Dis. 2024 Dec 10:S1473-3099(24)00810.
    >> Share

    November 2024
  22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    >> Share

  23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    >> Share

  24. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    >> Share

  25. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    >> Share

    October 2024
  26. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    >> Share

  27. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    >> Share

  28. WANG Y, So HC, Tsang NNY, Kwok SK, et al
    Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron BA.2, BA.4/5, and XBB dominance in Hong Kong: a prospective cohort study.
    Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00574.
    >> Share

  29. NAKAKUBO S
    Evolving COVID-19 symptoms and the ongoing course of research.
    Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00668.
    >> Share

  30. RAADSEN MP, Dahlke C, Fathi A, Hardtke S, et al
    Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
    Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423.
    >> Share

  31. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
    12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.
    Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00615.
    >> Share

  32. BATAWI SA, Alraddadi BM
    Revisiting MERS-CoV vaccination in the SARS-CoV-2 era.
    Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00453.
    >> Share

  33. RAMGOLAM A
    COVID-19 and sexual health rights in Africa.
    Lancet Infect Dis. 2024 Oct 3:S1473-3099(24)00662.
    >> Share

  34. DAS M
    Understanding outbreak preparedness.
    Lancet Infect Dis. 2024;24:1079.
    >> Share

    September 2024
  35. HAPPLE C, Hoffmann M, Kempf A, Nehlmeier I, et al
    Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.
    Lancet Infect Dis. 2024 Sep 25:S1473-3099(24)00603.
    >> Share

  36. WANG WX, Zhu FC
    COVID-19 immunisation strategies for adolescents.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00563.
    >> Share

  37. FIGUEROA AL, Torres D, Reyes-Acuna C, Matherne P, et al
    Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00501.
    >> Share

  38. TERSTAPPEN J, Hak SF, Bhan A, Bogaert D, et al
    The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
    Lancet Infect Dis. 2024 Sep 23:S1473-3099(24)00455.
    >> Share

  39. LAWSON M
    Globalisation and COVID-19.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00621.
    >> Share

  40. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    >> Share

  41. RUSSELL TW, Townsley H, Hellewell J, Gahir J, et al
    Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.
    Lancet Infect Dis. 2024 Sep 11:S1473-3099(24)00484.
    >> Share

  42. POLETTI P
    Kinetics of neutralising antibodies against SARS-CoV-2 variants.
    Lancet Infect Dis. 2024 Sep 11:S1473-3099(24)00513.
    >> Share

  43. WHELAN MG, Ware H, Ranka H, Kenny S, et al
    ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies.
    Lancet Infect Dis. 2024 Sep 10:S1473-3099(24)00585.
    >> Share

  44. HARRIS V, Holmes J, Gbinigie-Thompson O, Rahman NM, et al
    Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
    Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00431.
    >> Share


  45. Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00430.
    >> Share

  46. AL-ALY Z
    SARS-CoV-2 antivirals and post-COVID-19 condition.
    Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00436.
    >> Share

  47. ISA F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, et al
    Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
    Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00421.
    >> Share

  48. BLOTT J
    Facing COVID-19 in South Africa.
    Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00583.
    >> Share

  49. BAUER DLV
    Weighing up monoclonals and vaccination against COVID-19.
    Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00559.
    >> Share

  50. BURKI T
    First report from the UK COVID-19 Inquiry.
    Lancet Infect Dis. 2024;24:e555-e556.
    >> Share

  51. JESUDASON T
    Limited progress towards immunisation targets in 2023.
    Lancet Infect Dis. 2024;24:e553.
    >> Share

  52. BAGCCHI S
    Phyllis Dako-Gyeke.
    Lancet Infect Dis. 2024;24:950.
    >> Share

  53. TANUI CK, Ndembi N, Kebede Y, Tessema SK, et al
    Artificial intelligence to transform public health in Africa.
    Lancet Infect Dis. 2024;24:e542.
    >> Share

  54. FALSEY AR, Hosman T, Bastian AR, Vandenberghe S, et al
    Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.
    Lancet Infect Dis. 2024;24:1015-1024.
    >> Share

    August 2024
  55. KAKU Y, Uriu K, Okumura K, Ito J, et al
    Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant.
    Lancet Infect Dis. 2024 Aug 16:S1473-3099(24)00505.
    >> Share

  56. PHAM TM, Zhang Y, Nevers M, Li H, et al
    Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22).
    Lancet Infect Dis. 2024 Aug 13:S1473-3099(24)00416.
    >> Share

  57. KIRBY T
    Outbreaks compound Brazil's flooding disaster.
    Lancet Infect Dis. 2024;24:e490.
    >> Share

  58. KIRBY T
    Naomi Lucchi-from malaria to pandemic preparedness.
    Lancet Infect Dis. 2024;24:812.
    >> Share

  59. THE LANCET INFECTIOUS DISEASES
    Have we learned anything?
    Lancet Infect Dis. 2024;24:793.
    >> Share

  60. TOLEDO ME, Monteagudo Diaz S, Montenegro Calderon T, Kreppel K, et al
    Preparedness for emerging epidemic threats: detection of Oropouche circulation in Cuba.
    Lancet Infect Dis. 2024;24:e484.
    >> Share

  61. SHERWOOD-MARTIN H
    Poor leadership or institutional flaws?
    Lancet Infect Dis. 2024;24:816.
    >> Share

  62. BISBAS G
    Reflecting on the cost of recurrent conflicts for the USA.
    Lancet Infect Dis. 2024;24:813.
    >> Share

  63. KEDDY KH, Gobena T
    The continuing challenge of infectious diseases.
    Lancet Infect Dis. 2024;24:800-801.
    >> Share

    July 2024
  64. TOLENTINO JE, Lytras S, Ito J, Holmes EC, et al
    Recombination as an evolutionary driver of MERS-related coronavirus emergence.
    Lancet Infect Dis. 2024 Jul 24:S1473-3099(24)00461.
    >> Share

  65. GRAY GE, Mngadi K, Lavreys L, Nijs S, et al
    Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00358.
    >> Share

  66. CHOI MH, Wan EYF, Wong ICK, Chan EWY, et al
    Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study.
    Lancet Infect Dis. 2024 Jul 15:S1473-3099(24)00353.
    >> Share

  67. AKINOSOGLOU K, Gogos C
    Antiviral therapy for patients with COVID-19: mix and match.
    Lancet Infect Dis. 2024 Jul 15:S1473-3099(24)00407.
    >> Share

  68. BIJKER EM, Horn L, LaCourse S, MacLean EL, et al
    The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation-a consensus statement.
    Lancet Infect Dis. 2024 Jul 3:S1473-3099(24)00339.
    >> Share

  69. DUNSMUIR H
    Managing loss during the COVID-9 pandemic.
    Lancet Infect Dis. 2024;24:683.
    >> Share

  70. BUERANO CC, Morita K
    Single dose of Dengvaxia vaccine: is it a cause for alarm?
    Lancet Infect Dis. 2024;24:670-671.
    >> Share

    June 2024
  71. KAKU Y, Yo MS, Tolentino JE, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants.
    Lancet Infect Dis. 2024 Jun 27:S1473-3099(24)00415.
    >> Share

  72. GEERS D, Gommers L, Tan NH, Bogers S, et al
    Profiling the SARS-CoV-2-specific T-cell response.
    Lancet Infect Dis. 2024 Jun 20:S1473-3099(24)00377.
    >> Share

  73. DE LUSIGNAN S, Shi T, Fowler T, Andrews N, et al
    Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions.
    Lancet Infect Dis. 2024 Jun 3:S1473-3099(24)00352.
    >> Share

  74. HALL P
    Highlights of ESCMID Global 2024.
    Lancet Infect Dis. 2024;24:e357.
    >> Share

  75. VENKATESAN P
    Alasdair Macintosh Geddes.
    Lancet Infect Dis. 2024;24:577.
    >> Share

    May 2024
  76. KAKU Y, Uriu K, Kosugi Y, Okumura K, et al
    Virological characteristics of the SARS-CoV-2 KP.2 variant.
    Lancet Infect Dis. 2024 May 20:S1473-3099(24)00298.
    >> Share

  77. MOUSTSEN-HELMS IR, Bager P, Larsen TG, Moller FT, et al
    Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
    Lancet Infect Dis. 2024 May 15:S1473-3099(24)00220.
    >> Share

  78. INGHAMMAR M, Kahn F
    Immune evasiveness of SARS-CoV-2 variants and vaccine selection.
    Lancet Infect Dis. 2024 May 15:S1473-3099(24)00286.
    >> Share

  79. SORIANO V, Moreno-Torres V
    Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection.
    Lancet Infect Dis. 2024 May 3:S1473-3099(24)00258.
    >> Share

  80. WANG H, Wei Y, Hung CT, Lin G, et al
    Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
    Lancet Infect Dis. 2024 May 3:S1473-3099(24)00217.
    >> Share

  81. VENKATESAN P
    Tobias Welte.
    Lancet Infect Dis. 2024;24:457.
    >> Share

  82. MOODY J
    On the frontline during the COVID-19 pandemic.
    Lancet Infect Dis. 2024;24:464.
    >> Share

  83. KAZI F, Mushtaq A
    Nuria Izquierdo-Useros-fighting the good fight.
    Lancet Infect Dis. 2024;24:458.
    >> Share

  84. DE AMBROGI M
    A summer cold.
    Lancet Infect Dis. 2024;24:461.
    >> Share

  85. LIN DY, Huang S, Milinovich A, Duggal A, et al
    Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA.
    Lancet Infect Dis. 2024;24:e278-e280.
    >> Share

  86. KOCHER K, Moosmann C, Drost F, Schulein C, et al
    Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual.
    Lancet Infect Dis. 2024;24:e272-e274.
    >> Share

  87. KEDDY KH, Tadesse BT
    Inaccessible: health, wealth, governance, and equity in low-income and middle-income countries.
    Lancet Infect Dis. 2024;24:444-445.
    >> Share

    April 2024
  88. ARES-GOMEZ S, Mallah N, Santiago-Perez MI, Pardo-Seco J, et al
    Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
    Lancet Infect Dis. 2024 Apr 30:S1473-3099(24)00215.
    >> Share

  89. WONGNAK P, Schilling WHK, Jittamala P, Boyd S, et al
    Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00183.
    >> Share

  90. VISSER LG
    Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape.
    Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00254.
    >> Share

  91. BUONSENSO D, Tantisira KG
    Long COVID and SARS-CoV-2 persistence: new answers, more questions.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00216.
    >> Share

  92. ZUO W, He D, Liang C, Du S, et al
    The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.
    Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00171.
    >> Share

  93. JIN SL, Kolis J, Parker J, Proctor DA, et al
    Social histories of public health misinformation and infodemics: case studies of four pandemics.
    Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
    >> Share


  94. Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
    >> Share


  95. Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Apr 15:S1473-3099(24)00176.
    >> Share

  96. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
    Plasma-based antigen persistence in the post-acute phase of COVID-19.
    Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
    >> Share

  97. DE MENEZES NEVES PDM, Mohrbacher S, Lobato Vasques I, Barreira Cavalcante L, et al
    Renal infarction secondary to Aspergillus spp. embolism following COVID-19.
    Lancet Infect Dis. 2024;24:e266-e267.
    >> Share

    March 2024
  98. LARIVIERE Y, Matuvanga TZ, Osang'ir BI, Milolo S, et al
    Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised
    Lancet Infect Dis. 2024 Mar 26:S1473-3099(24)00058.
    >> Share

  99. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1.
    Lancet Infect Dis. 2024 Mar 21:S1473-3099(24)00155.
    >> Share

  100. DIXIT A, Bennett R, Ali K, Griffin C, et al
    Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101.
    >> Share

  101. LI SM, Zhu FC
    The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00157.
    >> Share


  102. Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
    >> Share

  103. ZHANG R, Hung IF
    Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.
    Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00156.
    >> Share

  104. BENNETT C, Woo W, Bloch M, Cheung K, et al
    Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
    Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077.
    >> Share

  105. BILSEN MP, Conroy SP, Schneeberger C, Platteel TN, et al
    A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study.
    Lancet Infect Dis. 2024 Mar 5:S1473-3099(23)00778.
    >> Share

  106. KOUTSAKOS M, Rockman S, Krammer F
    Is eradication of influenza B viruses possible?
    Lancet Infect Dis. 2024 Mar 4:S1473-3099(24)00132.
    >> Share

    February 2024
  107. POUKKA E, Auranen K, Baum U
    Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies.
    Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00106.
    >> Share

  108. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
    Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply.
    Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00107.
    >> Share

  109. PLEY C, Kampmann B
    Access to respiratory syncytial virus preventive tools for neonates and infants in Europe.
    Lancet Infect Dis. 2024 Feb 19:S1473-3099(24)00084.
    >> Share

  110. FAFI I, Assad Z, Lenglart L, Valtuille Z, et al
    Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices.
    Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00081.
    >> Share

  111. LI Y
    Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices - Author's reply.
    Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00082.
    >> Share

  112. MACHKOVECH HM, Hahn AM, Garonzik Wang J, Grubaugh ND, et al
    Persistent SARS-CoV-2 infection: significance and implications.
    Lancet Infect Dis. 2024 Feb 7:S1473-3099(23)00815.
    >> Share

  113. MARKING U, Bladh O, Aguilera K, Yang Y, et al
    Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
    Lancet Infect Dis. 2024;24:e80-e81.
    >> Share

  114. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
    Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
    Lancet Infect Dis. 2024 Feb 1:S1473-3099(24)00060.
    >> Share

  115. BERTRAN M, D'Aeth JC, Abdullahi F, Eletu S, et al
    Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
    Lancet Infect Dis. 2024 Feb 1:S1473-3099(23)00706.
    >> Share

    January 2024
  116. DENNING DW
    Global incidence and mortality of severe fungal disease.
    Lancet Infect Dis. 2024 Jan 12:S1473-3099(23)00692.
    >> Share

  117. COSSMANN A, Hoffmann M, Stankov MV, Lurken K, et al
    Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00783.
    >> Share

  118. KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al
    Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
    Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
    >> Share

  119. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
    Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.
    Lancet Infect Dis. 2024 Jan 5:S1473-3099(23)00746.
    >> Share

  120. KAKU Y, Okumura K, Padilla-Blanco M, Kosugi Y, et al
    Virological characteristics of the SARS-CoV-2 JN.1 variant.
    Lancet Infect Dis. 2024 Jan 3:S1473-3099(23)00813.
    >> Share

    December 2023
  121. CONG B, Koc U, Bandeira T, Bassat Q, et al
    Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
    Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00630.
    >> Share

  122. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
    Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00650.
    >> Share

  123. HERFST S, de Vries RD
    Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00734.
    >> Share

  124. MONTGOMERY MP, Morris SE, Rolfes MA, Kittikraisak W, et al
    The role of asymptomatic infections in influenza transmission: what do we really know.
    Lancet Infect Dis. 2023 Dec 18:S1473-3099(23)00619.
    >> Share

  125. YANG S, Yu Y, Xu Y, Jian F, et al
    Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.
    Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00744.
    >> Share

  126. GANDHI M
    Post-viral sequelae of COVID-19 and influenza.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
    >> Share

  127. XIE Y, Choi T, Al-Aly Z
    Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.
    Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684.
    >> Share

  128. RAMAN B, Ramasamy MN
    Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00735.
    >> Share

  129. LAU RI, Su Q, Lau ISF, Ching JYL, et al
    A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00685.
    >> Share

  130. ZUO F, Cao Y, Sun R, Yisimayi A, et al
    Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86.
    Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00732.
    >> Share

  131. CARR EJ, Dowgier G, Greenwood D, Herman LS, et al
    SARS-CoV-2 mucosal neutralising immunity after vaccination.
    Lancet Infect Dis. 2023 Dec 6:S1473-3099(23)00705.
    >> Share

  132. BURKI T
    UK Covid-19 Inquiry.
    Lancet Infect Dis. 2023;23:e516-e517.
    >> Share

  133. BAGCCHI S
    Boost for COVID-19 testing in the USA.
    Lancet Infect Dis. 2023;23:e514.
    >> Share

    November 2023
  134. DE LUSIGNAN S, Hobbs FR, Sheikh A
    Lessons from the English primary care sentinel network's response to the COVID-19 pandemic.
    Lancet Infect Dis. 2023 Nov 28:S1473-3099(23)00736.
    >> Share

  135. GOTTLIEB RL, Paredes R
    Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19.
    Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00633.
    >> Share

  136. FAN X, Dai X, Ling Y, Wu L, et al
    Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
    Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00577.
    >> Share

  137. STANKOV MV, Hoffmann M, Gutierrez Jauregui R, Cossmann A, et al
    Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
    Lancet Infect Dis. 2023 Nov 20:S1473-3099(23)00690.
    >> Share

  138. LASSAUNIERE R, Polacek C, Utko M, Sorensen KM, et al
    Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1.
    Lancet Infect Dis. 2023 Nov 7:S1473-3099(23)00682.
    >> Share

  139. JESUDASON T
    New licensing agreements for COVID-19.
    Lancet Infect Dis. 2023;23:e471.
    >> Share

    October 2023
  140. OLBRICH L, Verghese VP, Franckling-Smith Z, Sabi I, et al
    Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
    Lancet Infect Dis. 2023 Oct 30:S1473-3099(23)00491.
    >> Share

  141. SIMPSON CR, Robertson C, McMenamin J, Ritchie LD, et al
    Developing the EAVE III platform for future health crises.
    Lancet Infect Dis. 2023 Oct 12:S1473-3099(23)00626.
    >> Share

  142. GROBUSCH MP, Ruiz Del Portal Luyten C, Visser BJ, de Jong HK, et al
    Overcoming publication and dissemination bias in infectious diseases clinical trials.
    Lancet Infect Dis. 2023 Oct 11:S1473-3099(23)00455.
    >> Share

  143. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
    Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand.
    Lancet Infect Dis. 2023 Oct 6:S1473-3099(23)00620.
    >> Share

  144. FAUST JS
    The therapeutic validation of long COVID.
    Lancet Infect Dis. 2023;23:1096-1097.
    >> Share

    September 2023
  145. BRAMANTE C
    The power and pressure placed on clinicians and guideline panels.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00557.
    >> Share

  146. SCHILLING WHK, Jittamala P, Watson JA, Boyd S, et al
    Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00493.
    >> Share

  147. ONYWERA H, Ondoa P, Nfii F, Ogwell A, et al
    Boosting pathogen genomics and bioinformatics workforce in Africa.
    Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00394.
    >> Share

  148. SHEWARD DJ, Yang Y, Westerberg M, Oling S, et al
    Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.
    Lancet Infect Dis. 2023 Sep 27:S1473-3099(23)00588.
    >> Share

  149. YANG S, Yu Y, Jian F, Song W, et al
    Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.
    Lancet Infect Dis. 2023 Sep 19:S1473-3099(23)00573.
    >> Share

  150. URIU K, Ito J, Kosugi Y, Tanaka YL, et al
    Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
    Lancet Infect Dis. 2023 Sep 18:S1473-3099(23)00575.
    >> Share

  151. BLOM K, Fjallstrom P, Molnar C, Aberg M, et al
    SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters.
    Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00548.
    >> Share

  152. ZHANG L, Kempf A, Nehlmeier I, Cossmann A, et al
    Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3.
    Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00547.
    >> Share

  153. KAKU Y, Kosugi Y, Uriu K, Ito J, et al
    Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00553.
    >> Share

  154. WANG Q, Guo Y, Zhang RM, Ho J, et al
    Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.
    Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00555.
    >> Share

    August 2023
  155. MARANDA B, Labbe SM, Lurquin M, Brabant P, et al
    Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
    Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00393.
    >> Share

  156. WANG Y, Cao B
    The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases.
    Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00454.
    >> Share

  157. ABO YN, Jamrozik E, McCarthy JS, Roestenberg M, et al
    Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy.
    Lancet Infect Dis. 2023 Aug 10:S1473-3099(23)00294.
    >> Share

  158. GRANT R, Benamouzig D, Catton H, Cheng VC, et al
    COVID-19 pandemic: a catalyst for accelerating global action on patient safety.
    Lancet Infect Dis. 2023 Aug 9:S1473-3099(23)00485.
    >> Share

  159. TAN CY, Chiew CJ, Pang D, Lee VJ, et al
    Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
    Lancet Infect Dis. 2023 Aug 2:S1473-3099(23)00373.
    >> Share

  160. THE LANCET INFECTIOUS DISEASES
    Where are the long COVID trials?
    Lancet Infect Dis. 2023;23:879.
    >> Share

    July 2023
  161. MADHI SA, Feikin DR
    Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19?
    Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00425.
    >> Share

  162. MATEO-URDIALES A, Sacco C, Fotakis EA, Del Manso M, et al
    Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
    Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00374.
    >> Share

  163. COHN H, Bloom N, Cai GY, Clark JJ, et al
    Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
    Lancet Infect Dis. 2023 Jul 17:S1473-3099(23)00352.
    >> Share

  164. CERQUEIRA-SILVA T, Boaventura VS, Barral-Netto M
    Effectiveness of monovalent and bivalent COVID-19 vaccines.
    Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00379.
    >> Share

  165. KIRSEBOM FCM, Andrews N, Stowe J, Ramsay M, et al
    Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
    Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00365.
    >> Share

  166. SCHAEFER GO, Atuire CA, Kaur S, Parker M, et al
    The importance of getting the ethics right in a pandemic treaty.
    Lancet Infect Dis. 2023 Jul 5:S1473-3099(23)00364.
    >> Share

  167. AL-ALY Z
    Prevention of long COVID: progress and challenges.
    Lancet Infect Dis. 2023;23:776-777.
    >> Share

  168. CARR EJ, Wu MY, Gahir J, Harvey R, et al
    Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
    Lancet Infect Dis. 2023;23:781-784.
    >> Share

    June 2023
  169. NAKAKUBO S, Kishida N, Okuda K, Kamada K, et al
    Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
    Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00271.
    >> Share

  170. TSUZUKI S
    The future of COVID-19 surveillance in Japan.
    Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00292.
    >> Share

  171. CRODA J
    Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00363.
    >> Share

  172. LI JX, Hou LH, Gou JB, Yin ZD, et al
    Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00350.
    >> Share

  173. SOLERA JT, Ierullo M, Arbol BG, Mavandadnejad F, et al
    Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00357.
    >> Share

  174. YAMIN D, Yechezkel M, Arbel R, Beckenstein T, et al
    Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00207.
    >> Share

  175. MADHI SA, Izu A
    Safety of COVID-19 booster dose: is the juice worth the squeeze?
    Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00296.
    >> Share

  176. LEE IT, Cosgrove CA, Moore P, Bethune C, et al
    Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
    Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00295.
    >> Share

  177. SHANG L, Cao B
    Adapted vaccine strategy: facing the persistent challenges of COVID-19.
    Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00370.
    >> Share

  178. LIN DY, Xu Y, Gu Y, Zeng D, et al
    Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
    Lancet Infect Dis. 2023 Jun 16:S1473-3099(23)00272.
    >> Share

  179. BRAMANTE CT, Buse JB, Liebovitz DM, Nicklas JM, et al
    Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
    Lancet Infect Dis. 2023 Jun 8:S1473-3099(23)00299.
    >> Share

  180. WALIA K, Mendelson M, Kang G, Venkatasubramanian R, et al
    How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00124.
    >> Share

  181. ALAKIJA A
    Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats.
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00279.
    >> Share

  182. KANA BD, Arbuthnot P, Botwe BK, Choonara YE, et al
    Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
    Lancet Infect Dis. 2023 Jun 5:S1473-3099(22)00878.
    >> Share

    May 2023
  183. ZHANG R, Hung IF
    CS-2034 mRNA vaccine: a new option for COVID-19 infection?
    Lancet Infect Dis. 2023 May 19:S1473-3099(23)00277.
    >> Share

  184. WU JD, Li JX, Liu J, Wang HM, et al
    Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged >/=18 years: a randomised, double-blind, phase 2b trial.
    Lancet Infect Dis. 2023 May 19:S1473-3099(23)00199.
    >> Share

  185. BHATIA S, Imai N, Watson OJ, Abbood A, et al
    Lessons from COVID-19 for rescalable data collection.
    Lancet Infect Dis. 2023 May 4:S1473-3099(23)00121.
    >> Share

  186. LEE NR, King A, Vigil D, Mullaney D, et al
    Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future.
    Lancet Infect Dis. 2023 May 3:S1473-3099(23)00190.
    >> Share

  187. YAMASOBA D, Uriu K, Plianchaisuk A, Kosugi Y, et al
    Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
    Lancet Infect Dis. 2023 May 3:S1473-3099(23)00278.
    >> Share

  188. IZU A, Nunes MC, Solomon F, Baillie V, et al
    All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
    Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200.
    >> Share

  189. LEVY C, Cohen R
    Infectious diseases in the COVID-19 era: gaps between countries.
    Lancet Infect Dis. 2023 May 1:S1473-3099(23)00198.
    >> Share

    April 2023
  190. JUAN-GINER A, Namulwana ML, Kimathi D, Grantz KH, et al
    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
    Lancet Infect Dis. 2023 Apr 28:S1473-3099(23)00131.
    >> Share

  191. MONACH PA, Branch-Elliman W
    More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.
    Lancet Infect Dis. 2023 Apr 26:S1473-3099(23)00274.
    >> Share

  192. VASIN AV, Stukova MA
    Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2.
    Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00189.
    >> Share

  193. TAN NH, Geers D, Sablerolles RSG, Rietdijk WJR, et al
    Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00140.
    >> Share

  194. STOLIAROFF-PEPIN A, Harder T
    Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations.
    Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00187.
    >> Share

  195. ARBEL R, Peretz A, Sergienko R, Friger M, et al
    Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00122.
    >> Share

  196. JENKIN D, Wright D, Folegatti PM, Platt A, et al
    Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
    Lancet Infect Dis. 2023 Apr 12:S1473-3099(23)00068.
    >> Share

  197. SOLERA JT, Arbol BG, Ferreira VH, Kurtesi A, et al
    Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.
    Lancet Infect Dis. 2023 Apr 5:S1473-3099(23)00208.
    >> Share

  198. IWASAKI A, Putrino D
    Why we need a deeper understanding of the pathophysiology of long COVID.
    Lancet Infect Dis. 2023;23:393-395.
    >> Share

  199. URAKI R, Ito M, Kiso M, Yamayoshi S, et al
    Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
    Lancet Infect Dis. 2023;23:402-403.
    >> Share

    March 2023
  200. WANG Q, Bowen A, Tam AR, Valdez R, et al
    SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
    Lancet Infect Dis. 2023 Mar 29:S1473-3099(23)00181.
    >> Share

  201. EYRE DW, Futschik M, Tunkel S, Wei J, et al
    Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
    Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00129.
    >> Share

  202. PRESTEDGE J, Williamson DA
    The performance of rapid antigen tests against SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00186.
    >> Share

  203. WILKINS D, Langedijk AC, Lebbink RJ, Morehouse C, et al
    Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
    Lancet Infect Dis. 2023 Mar 17:S1473-3099(23)00062.
    >> Share

  204. LEWNARD JA, McLaughlin JM, Malden D, Hong V, et al
    Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
    Lancet Infect Dis. 2023 Mar 15:S1473-3099(23)00118.
    >> Share

  205. TAN CY, Chiew CJ, Pang D, Lee VJ, et al
    Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
    Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00060.
    >> Share

  206. BOYTON RJ, Altmann DM
    Imprinted hybrid immunity against XBB reinfection.
    Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00138.
    >> Share

  207. CHEMAITELLY H, Ayoub HH, Tang P, Coyle P, et al
    Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
    Lancet Infect Dis. 2023 Mar 10:S1473-3099(23)00058.
    >> Share

  208. URAKI R, Ito M, Kiso M, Yamayoshi S, et al
    Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
    Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00132.
    >> Share

  209. KUIKEN T, Fouchier RAM, Koopmans MPG
    Being ready for the next influenza pandemic?
    Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00117.
    >> Share

  210. KIRBY T
    Alemka Markotic-from hantavirus to COVID-19.
    Lancet Infect Dis. 2023;23:292.
    >> Share

  211. SOTO-RIFO R
    Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4.
    Lancet Infect Dis. 2023;23:262-263.
    >> Share

    February 2023
  212. HUANG J, Zhao S, Chong KC, Zhou Y, et al
    Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen.
    Lancet Infect Dis. 2023 Feb 17:S1473-3099(23)00112.
    >> Share

  213. WONG CKH, Lau KTK, Au ICH, Lau EHY, et al
    Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Lancet Infect Dis. 2023 Feb 13:S1473-3099(22)00873.
    >> Share

  214. PETROSILLO N
    SARS-CoV-2 rebound with and without antivirals.
    Lancet Infect Dis. 2023 Feb 13:S1473-3099(23)00063.
    >> Share

  215. AGGARWAL NR, Molina KC, Beaty LE, Bennett TD, et al
    Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00011.
    >> Share

  216. WONG CKH, Lau KTK, Leung GM
    Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00056.
    >> Share

  217. YUE C, Song W, Wang L, Jian F, et al
    ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
    Lancet Infect Dis. 2023 Feb 3:S1473-3099(23)00010.
    >> Share

  218. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents.
    Lancet Infect Dis. 2023 Feb 1:S1473-3099(23)00005.
    >> Share

    January 2023
  219. URIU K, Ito J, Zahradnik J, Fujita S, et al
    Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
    Lancet Infect Dis. 2023 Jan 31:S1473-3099(23)00051.
    >> Share

  220. HOEHL S, Ciesek S
    Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
    Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00007.
    >> Share

  221. HE G, Jones JA, Sun W
    COVID-19 travel policies for people from China and discrimination.
    Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00052.
    >> Share

  222. GIACOBBE DR, Bassetti M
    Too many antibiotics for patients with COVID-19 despite low bacterial infections.
    Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00866.
    >> Share

  223. CHEN JZ, Hoang HL, Yaskina M, Kabbani D, et al
    Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.
    Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00832.
    >> Share

  224. BOAVENTURA VS, Cerqueira-Silva T, Barral-Netto M
    The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era.
    Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00880.
    >> Share

  225. BOBROVITZ N, Ware H, Ma X, Li Z, et al
    Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
    Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00801.
    >> Share

  226. FADLYANA E, Setiabudi D, Kartasasmita CB, Putri ND, et al
    Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial
    Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00800.
    >> Share

  227. MARKING U, Bladh O, Havervall S, Svensson J, et al
    7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.
    Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00834.
    >> Share

  228. NILLES EJ, Paulino CT, de St Aubin M, Duke W, et al
    Tracking immune correlates of protection for emerging SARS-CoV-2 variants.
    Lancet Infect Dis. 2023 Jan 11:S1473-3099(23)00001.
    >> Share

  229. BRADY OJ, Hofmann B, Colon-Gonzalez FJ, Gibb R, et al
    Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting.
    Lancet Infect Dis. 2023 Jan 6:S1473-3099(23)00003.
    >> Share

  230. ARORA P, Cossmann A, Schulz SR, Ramos GM, et al
    Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.
    Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00831.
    >> Share

  231. MALATO J, Ribeiro RM, Fernandes E, Leite PP, et al
    Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months.
    Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00833.
    >> Share

    December 2022
  232. NACHEGA JB, Nsanzimana S, Rawat A, Wilson LA, et al
    Advancing detection and response capacities for emerging and re-emerging pathogens in Africa.
    Lancet Infect Dis. 2022 Dec 20:S1473-3099(22)00723.
    >> Share

  233. TSALIK EL, Rouphael NG, Sadikot RT, Rodriguez-Barradas MC, et al
    Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial.
    Lancet Infect Dis. 2022 Dec 13:S1473-3099(22)00735.
    >> Share

  234. TSANG NNY, So HC, Cowling BJ, Leung GM, et al
    Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Lancet Infect Dis. 2022 Dec 12:S1473-3099(22)00732.
    >> Share

  235. BRYANT OK, Man KKC, Jani YH, Wong ICK, et al
    Antibiotic prescribing in general practice during COVID-19 and beyond.
    Lancet Infect Dis. 2022 Dec 7:S1473-3099(22)00814.
    >> Share

  236. HOFFMANN M, Behrens GMN, Arora P, Kempf A, et al
    Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation.
    Lancet Infect Dis. 2022 Dec 5:S1473-3099(22)00792.
    >> Share

  237. FLORENTINO PTV, Alves FJO, Cerqueira-Silva T, de Araujo Oliveira V, et al
    Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil.
    Lancet Infect Dis. 2022;22:1669-1670.
    >> Share

  238. DEN HARTOG G, van Kasteren PB, Schepp RM, Teirlinck AC, et al
    Decline of RSV-specific antibodies during the COVID-19 pandemic.
    Lancet Infect Dis. 2022 Dec 1:S1473-3099(22)00763.
    >> Share

    November 2022
  239. POWELL AA, Kirsebom F, Stowe J, Ramsay ME, et al
    Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-neg
    Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00729.
    >> Share

  240. IRVING SA, Buchan SA
    Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination.
    Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00759.
    >> Share

  241. ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
    Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.
    Lancet Infect Dis. 2022 Nov 18:S1473-3099(22)00733.
    >> Share

  242. LINDHOLM DA, Kalil AC
    Deja vu all over again? Monkeypox and the urgent need for randomised controlled trials.
    Lancet Infect Dis. 2022 Nov 15. pii: S1473-3099(22)00722.
    >> Share

  243. KENNEDY RB
    Monkeypox infection creates immune signatures of disease progression.
    Lancet Infect Dis. 2022 Nov 7. pii: S1473-3099(22)00691.
    >> Share

  244. NICHOLS RM, Deveau C, Upadhyaya H
    Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic.
    Lancet Infect Dis. 2022;22:1531.
    >> Share

    October 2022
  245. WANG Q, Li Z, Ho J, Guo Y, et al
    Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
    Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00694.
    >> Share

  246. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages.
    Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00693.
    >> Share

  247. PRENDECKI M, Willicombe M
    SARS-CoV-2 vaccine strategies in kidney transplant recipients.
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00666.
    >> Share

  248. KHO MML, Messchendorp AL, Frolke SC, Imhof C, et al
    Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00650.
    >> Share

  249. DORON S, Gandhi M
    New boosters are here! Who should receive them and when?
    Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00688.
    >> Share

  250. TARTOF SY, Slezak JM, Puzniak L, Hong V, et al
    BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.
    Lancet Infect Dis. 2022 Oct 25. pii: S1473-3099(22)00692.
    >> Share

  251. MADHI SA, Kwatra G, Richardson SI, Koen AL, et al
    Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
    Lancet Infect Dis. 2022 Oct 20. pii: S1473-3099(22)00596.
    >> Share

  252. STANDING JF, Agyeman AA
    Learning and confirming in publicly funded antiviral trials.
    Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00665.
    >> Share

  253. KHOO SH, FitzGerald R, Saunders G, Middleton C, et al
    Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00644.
    >> Share

  254. HANSEN CH, Friis NU, Bager P, Stegger M, et al
    Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
    Lancet Infect Dis. 2022 Oct 18. pii: S1473-3099(22)00595.
    >> Share

  255. ANGELO KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, et al
    Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
    Lancet Infect Dis. 2022 Oct 7. pii: S1473-3099(22)00651.
    >> Share

  256. LLEWELYN MJ, Budgell EP, Laskawiec-Szkonter M, Cross ELA, et al
    Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.
    Lancet Infect Dis. 2022 Oct 4. pii: S1473-3099(22)00508.
    >> Share

  257. RANSCOMBE P
    Dr Hammond's COVID-19 inquiry.
    Lancet Infect Dis. 2022;22:1433.
    >> Share

    September 2022
  258. CHIEW CJ, Premikha M, Chong CY, Wei WE, et al
    Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Lancet Infect Dis. 2022 Sep 28. pii: S1473-3099(22)00573.
    >> Share

  259. JIAN F, Yu Y, Song W, Yisimayi A, et al
    Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
    Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
    >> Share

  260. MAITEKI-SEBUGUZI C, Gonahasa S, Kamya MR, Katureebe A, et al
    Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign.
    Lancet Infect Dis. 2022 Sep 26. pii: S1473-3099(22)00469.
    >> Share

  261. BANDYOPADHYAY AS, Zipursky S
    A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.
    Lancet Infect Dis. 2022 Sep 23. pii: S1473-3099(22)00582.
    >> Share

  262. CARAZO S, Skowronski DM, Brisson M, Barkati S, et al
    Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
    Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00578.
    >> Share

  263. HUI DS
    Hybrid immunity and strategies for COVID-19 vaccination.
    Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00640.
    >> Share

  264. ARORA P, Nehlmeier I, Kempf A, Cossmann A, et al
    Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.
    Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00591.
    >> Share

  265. POLAND GA, Kennedy RB, Tosh PK
    Prevention of monkeypox with vaccines: a rapid review.
    Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00574.
    >> Share

  266. HARDT K, Vandebosch A, Sadoff J, Le Gars M, et al
    Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Infect Dis. 2022 Sep 13. pii: S1473-3099(22)00506.
    >> Share

  267. AMIR O, Goldberg Y, Mandel M, Bar-On YM, et al
    Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
    Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00527.
    >> Share

  268. IRVING SA, Klein NP
    COVID-19 vaccination protects children and adolescents.
    Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00575.
    >> Share

  269. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
    Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage.
    Lancet Infect Dis. 2022 Sep 6. pii: S1473-3099(22)00580.
    >> Share

  270. LAZARUS R, Querton B, Corbic Ramljak I, Dewasthaly S, et al
    Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
    Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00502.
    >> Share

  271. GEURTSVANKESSEL CH, de Vries RD
    Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
    Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00517.
    >> Share

  272. BARDSLEY M, Morbey RA, Hughes HE, Beck CR, et al
    Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study.
    Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00525.
    >> Share

  273. BILLARD MN, Bont LJ
    Quantifying the RSV immunity debt following COVID-19: a public health matter.
    Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00544.
    >> Share

    August 2022
  274. WELLS CR, Galvani AP
    Tackling the politicisation of COVID-19 data reporting through open access data sharing.
    Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00505.
    >> Share

  275. DONG E, Ratcliff J, Goyea TD, Katz A, et al
    The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned.
    Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00434.
    >> Share

  276. AABY P, Netea MG, Benn CS
    Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.
    Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00498.
    >> Share

  277. GAVRIILAKI E, Kokoris S
    COVID-19 sequelae: can long-term effects be predicted?
    Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00529.
    >> Share

  278. PERICO N, Cortinovis M, Suter F, Remuzzi G, et al
    Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.
    Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00433.
    >> Share

  279. DEUEL JW, Lauria E, Lovey T, Zweifel S, et al
    Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo).
    Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00449.
    >> Share

  280. ZAREBSKA-MICHALUK D, Flisiak R
    Early oral antiviral use in patients hospitalised with COVID-19.
    Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00522.
    >> Share

  281. WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
    Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00507.
    >> Share

  282. HALFORD F, Nash S, Tessier E, Kall M, et al
    Variation in reported SARS-CoV-2 cases after testing policy changes.
    Lancet Infect Dis. 2022 Aug 23. pii: S1473-3099(22)00572.
    >> Share

  283. FAUST JS, Renton B, Chen AJ, Du C, et al
    Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state.
    Lancet Infect Dis. 2022 Aug 22. pii: S1473-3099(22)00547.
    >> Share

  284. FRANCO-PAREDES C, Rodriguez-Morales AJ, Henao-Martinez AF, Carrasco P, et al
    The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era.
    Lancet Infect Dis. 2022 Aug 16. pii: S1473-3099(22)00548.
    >> Share

  285. ELLINGTON S, Olson CK
    Safety of mRNA COVID-19 vaccines during pregnancy.
    Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00443.
    >> Share

  286. SADARANGANI M, Soe P, Shulha HP, Valiquette L, et al
    Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
    Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00426.
    >> Share

  287. MALLORY RM, Formica N, Pfeiffer S, Wilkinson B, et al
    Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00420.
    >> Share

  288. RYCKMAN T, Robsky K, Cilloni L, Zawedde-Muyanja S, et al
    Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.
    Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00500.
    >> Share

  289. FLORENTINO PTV, Millington T, Cerqueira-Silva T, Robertson C, et al
    Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
    Lancet Infect Dis. 2022 Aug 8. pii: S1473-3099(22)00451.
    >> Share

  290. MARTIN GE, Taiaroa G, Taouk ML, Savic I, et al
    Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices.
    Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00512.
    >> Share

    July 2022
  291. MCMENAMIN ME, Nealon J, Lin Y, Wong JY, et al
    Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
    Lancet Infect Dis. 2022 Jul 15. pii: S1473-3099(22)00345.
    >> Share

  292. SUN F, Lin Y, Wang X, Gao Y, et al
    Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
    Lancet Infect Dis. 2022 Jul 14. pii: S1473-3099(22)00430.
    >> Share

  293. HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
    Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
    >> Share

  294. FOCOSI D, McConnell S, Casadevall A, Cappello E, et al
    Monoclonal antibody therapies against SARS-CoV-2.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00311.
    >> Share

  295. GOTTLIEB RL, Razonable RR
    Stewardship of COVID-19 volunteers by nested trial design.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00429.
    >> Share

  296. BALAKRISHNAN VS
    2 years of the Access to COVID-19 Tools-Accelerator.
    Lancet Infect Dis. 2022;22:948.
    >> Share

  297. SPANER C, Goubran M, Setiadi A, Chen LYC, et al
    COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes.
    Lancet Infect Dis. 2022;22:937-938.
    >> Share

    June 2022
  298. ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
    Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.
    Lancet Infect Dis. 2022 Jun 28. pii: S1473-3099(22)00422.
    >> Share

  299. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
    Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled tr
    Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00272.
    >> Share

  300. MARIATULQABTIAH AR, Buttigieg KR
    COVID-19 vaccinations for children.
    Lancet Infect Dis. 2022 Jun 24. pii: S1473-3099(22)00414.
    >> Share

  301. WELLS CR, Galvani AP
    The global impact of disproportionate vaccination coverage on COVID-19 mortality.
    Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00417.
    >> Share

  302. WATSON OJ, Barnsley G, Toor J, Hogan AB, et al
    Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
    Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00320.
    >> Share

  303. HIGDON MM, Baidya A, Walter KK, Patel MK, et al
    Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant.
    Lancet Infect Dis. 2022 Jun 22. pii: S1473-3099(22)00409.
    >> Share

  304. VADREVU KM, Reddy S, Jogdand H, Ganneru B, et al
    Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
    Lancet Infect Dis. 2022 Jun 16. pii: S1473-3099(22)00307.
    >> Share

  305. BLOM K, Marking U, Havervall S, Norin NG, et al
    Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.
    Lancet Infect Dis. 2022 Jun 9. pii: S1473-3099(22)00362.
    >> Share

  306. YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
    Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
    Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
    >> Share

  307. USHER AD
    FIND documents dramatic reduction in COVID-19 testing.
    Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00376.
    >> Share

  308. MONGE S, Rojas-Benedicto A, Olmedo C, Mazagatos C, et al
    Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
    Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00292.
    >> Share

  309. ADER F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, et al
    Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.
    Lancet Infect Dis. 2022;22:764-765.
    >> Share

  310. BRADY OJ, Tian H
    Additional considerations for assessing COVID-19 impact on dengue transmission - Authors' reply.
    Lancet Infect Dis. 2022;22:763.
    >> Share

  311. YEK C, Pacheco AR, Lon C, Leang R, et al
    Additional considerations for assessing COVID-19 impact on dengue transmission.
    Lancet Infect Dis. 2022;22:762-763.
    >> Share

    May 2022
  312. TRAEGER MW, Guy R, Asselin J, Patel P, et al
    Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
    >> Share

  313. KIRSEBOM FCM, Andrews N, Stowe J, Toffa S, et al
    COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
    Lancet Infect Dis. 2022 May 24. pii: S1473-3099(22)00309.
    >> Share

  314. BURN E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, et al
    Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.
    Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00223.
    >> Share

  315. WHITELEY W, Wood A
    Risk of arterial and venous thromboses after COVID-19.
    Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00314.
    >> Share

  316. LOUBET P, Launay O
    What a second booster dose of mRNA COVID-19 vaccines tells us.
    Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00282.
    >> Share

  317. MUNRO APS, Feng S, Janani L, Cornelius V, et al
    Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomis
    Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00271.
    >> Share

  318. ROMERO-OLMEDO AJ, Schulz AR, Hochstatter S, Gupta DD, et al
    Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years.
    Lancet Infect Dis. 2022;22:588-589.
    >> Share

  319. SANCHEZ L, Oviedo Rouco S, Pifano M, Ojeda DS, et al
    Antibody durability at 1 year after Sputnik V vaccination.
    Lancet Infect Dis. 2022;22:589-590.
    >> Share

    April 2022
  320. ODONE A, Vigezzi GP, Baldanti F
    Implications of COVID-19 vaccine effectiveness waning for public health.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00233.
    >> Share

  321. ADLHOCH C, Gomes HC
    Sustainability of surveillance systems for SARS-CoV-2.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00174.
    >> Share

  322. SHEIKH A, Kerr S, Woolhouse M, McMenamin J, et al
    Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00141.
    >> Share

  323. BAGER P, Wohlfahrt J, Bhatt S, Stegger M, et al
    Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
    Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00154.
    >> Share

  324. SMOLENOV I, Han HH, Li P, Baccarini C, et al
    Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
    Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00144.
    >> Share

  325. LI JX, Zhu FC
    The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2.
    Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00162.
    >> Share

  326. LORTHE E, Bellon M, Berthelot J, Michielin G, et al
    A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland.
    Lancet Infect Dis. 2022 Apr 14. pii: S1473-3099(22)00267.
    >> Share

  327. CRAWSHAW AF, Farah Y, Deal A, Rustage K, et al
    Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review.
    Lancet Infect Dis. 2022 Apr 13. pii: S1473-3099(22)00066.
    >> Share

  328. ARORA P, Zhang L, Rocha C, Sidarovich A, et al
    Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3.
    Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(22)00224.
    >> Share

  329. WANG B, Giles L, Andraweera P, McMillan M, et al
    Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
    Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(21)00754.
    >> Share

  330. MENNI C, May A, Polidori L, Louca P, et al
    COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Lancet Infect Dis. 2022 Apr 8. pii: S1473-3099(22)00146.
    >> Share

  331. MUTHU V, Agarwal R, Patel A, Kathirvel S, et al
    Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.
    Lancet Infect Dis. 2022 Apr 4. pii: S1473-3099(22)00124.
    >> Share

  332. KIRBY T
    Kanta Subbarao-confronting influenza and COVID-19.
    Lancet Infect Dis. 2022;22:460.
    >> Share

  333. BURKI T
    Hong Kong's fifth COVID-19 wave-the worst yet.
    Lancet Infect Dis. 2022;22:455-456.
    >> Share

  334. THIRUVENGADAM R, Awasthi A, Bhatnagar S, Garg PK, et al
    Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply.
    Lancet Infect Dis. 2022;22:447.
    >> Share

  335. CHAKRABARTI S, Chakrabarti SS, Chandan G, Kaur U, et al
    Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India.
    Lancet Infect Dis. 2022;22:446-447.
    >> Share

  336. DYSON L
    Modelling results on the impact of COVID-19 testing in schools.
    Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00163.
    >> Share

  337. COLOSI E, Bassignana G, Contreras DA, Poirier C, et al
    Screening and vaccination against COVID-19 to minimise school closure: a modelling study.
    Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00138.
    >> Share

    March 2022
  338. NORDSTROM P, Ballin M, Nordstrom A
    Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00143.
    >> Share

  339. GARG PK, Thiruvengadam R
    Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00207.
    >> Share

  340. TAN HX, Juno JA
    Interplay of infection and vaccination in long-term protection from COVID-19.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00210.
    >> Share

  341. CERQUEIRA-SILVA T, Andrews JR, Boaventura VS, Ranzani OT, et al
    Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
    Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00140.
    >> Share

  342. DAL-RE R, Becker SL, Bottieau E, Holm S, et al
    Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
    Lancet Infect Dis. 2022 Mar 29. pii: S1473-3099(22)00119.
    >> Share

  343. POWELL AA, Kirsebom F, Stowe J, McOwat K, et al
    Effectiveness of BNT162b2 against COVID-19 in adolescents.
    Lancet Infect Dis. 2022 Mar 21. pii: S1473-3099(22)00177.
    >> Share

  344. SHEWARD DJ, Kim C, Ehling RA, Pankow A, et al
    Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Lancet Infect Dis. 2022 Mar 17. pii: S1473-3099(22)00129.
    >> Share

  345. PARKER A, Dawood H
    SARS-CoV-2 transmission: time to rethink public health strategy.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00137.
    >> Share

  346. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
    SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
    >> Share

  347. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
    Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
    >> Share

  348. ECKHARDT CM, O'Donnell MR
    CD24Fc: an emerging COVID-19 therapy.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00125.
    >> Share

  349. PARKER EPK, Desai S, Marti M, O'Brien KL, et al
    Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?
    Lancet Infect Dis. 2022 Mar 9. pii: S1473-3099(22)00178.
    >> Share

  350. KRANTZ MS, Phillips EJ
    COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
    Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00123.
    >> Share

  351. ROSENBLUM HG, Gee J, Liu R, Marquez PL, et al
    Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
    Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00054.
    >> Share

  352. DEAN AS, Tosas Auguet O, Glaziou P, Zignol M, et al
    25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(21)00808.
    >> Share

  353. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
    World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
    >> Share

  354. SASMONO RT, Santoso MS
    Movement dynamics: reduced dengue cases during the COVID-19 pandemic.
    Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00062.
    >> Share

  355. CHEN Y, Li N, Lourenco J, Wang L, et al
    Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study.
    Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00025.
    >> Share

  356. KIRBY T
    Wolfgang Preiser-co-discoverer of SARS-CoV-2 variants.
    Lancet Infect Dis. 2022;22:326.
    >> Share

  357. BURKI T
    Education services in crisis due to COVID-19.
    Lancet Infect Dis. 2022;22:321-322.
    >> Share

  358. SZEPESSY E, Arlett P, Sweeney F, Broich K, et al
    COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
    Lancet Infect Dis. 2022;22:315-316.
    >> Share

  359. DEPOORTERE E, Sowinski S, van Hengel A, Kerstiens B, et al
    COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
    Lancet Infect Dis. 2022;22:315.
    >> Share

  360. GUPTA S, Saarikko M, Pfutzner A, Raisanen IT, et al
    Compromised periodontal status could increase mortality for patients with COVID-19.
    Lancet Infect Dis. 2022;22:314.
    >> Share

  361. VILLAR JC, Gumisiriza N, Abreu LG, Maude RJ, et al
    Defining post-COVID condition.
    Lancet Infect Dis. 2022;22:316-317.
    >> Share

  362. SCHLAGENHAUF P, Deuel J
    Concerts and COVID: can the beat go on?
    Lancet Infect Dis. 2022;22:299-301.
    >> Share

    February 2022
  363. COBELENS F, Suri RK, Helinski M, Makanga M, et al
    Accelerating research and development of new vaccines against tuberculosis: a global roadmap.
    Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(21)00810.
    >> Share

  364. VANSHYLLA K, Tober-Lau P, Gruell H, Munn F, et al
    Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults.
    Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(22)00135.
    >> Share

  365. ABEYWICKREMA M, Goodman AL
    COVID-19 vaccine results might inform malaria vaccine strategies.
    Lancet Infect Dis. 2022 Feb 24. pii: S1473-3099(22)00139.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016